EORTC Bladder Cancer Calculator
Calculate recurrence and progression risk for non-muscle invasive bladder cancer
EORTC Risk Assessment
EORTC Scoring System
| Risk Factor | Category | Recurrence Points | Progression Points |
|---|---|---|---|
| Number of tumors | Single | 0 | 0 |
| 2-7 | 3 | 3 | |
| ≥8 | 6 | 3 | |
| Tumor diameter | <3 cm | 0 | 0 |
| ≥3 cm | 3 | 3 | |
| Prior recurrence | Primary | 0 | 0 |
| ≤1 rec/year | 2 | 2 | |
| >1 rec/year | 4 | 2 | |
| Stage | Ta | 0 | 0 |
| T1 | 1 | 4 | |
| Concomitant CIS | No | 0 | 0 |
| Yes | 1 | 6 | |
| Grade | G1 | 0 | 0 |
| G2 | 1 | 0 | |
| G3 | 2 | 5 |
Risk Categories
Low Risk
Low recurrence (<50%) and progression (<10%) probability
Intermediate Risk
Moderate risk requiring active surveillance
High Risk
High probability of recurrence and progression
Key Terms
NMIBC
Non-muscle invasive bladder cancer
CIS
Carcinoma in situ - flat high-grade lesion
Ta
Non-invasive papillary carcinoma
T1
Invasion into subepithelial connective tissue
BCG
Bacillus Calmette-Guérin immunotherapy
Understanding EORTC Bladder Cancer Risk Assessment
About Bladder Cancer
Bladder cancer is the most common urinary tract malignancy, primarily affecting people over 60 years old. At diagnosis, approximately 75% of patients have non-muscle invasive bladder cancer (NMIBC), which generally has a good survival rate but significant potential for recurrence and progression.
Risk Factors
- •Smoking (biggest risk factor)
- •Chemical exposure (industrial chemicals, dyes)
- •Chronic bladder inflammation
- •Previous cancer treatment
EORTC Scoring System
The European Organisation for Research and Treatment of Cancer (EORTC) developed this risk calculator using data from nearly 2,600 patients. It predicts the probability of tumor recurrence and progression based on six clinical and pathological factors.
Clinical Application
- •Guides treatment decision-making
- •Determines follow-up frequency
- •Patient counseling and prognosis
- •Selection for adjuvant therapy
⚠️ Important Medical Disclaimer
This calculator is for educational purposes only and should not replace professional medical advice.
- • Always consult with a qualified urologist or oncologist for treatment decisions
- • Individual patient factors may influence prognosis beyond these parameters
- • Treatment recommendations should consider patient comorbidities and preferences
- • Regular follow-up and monitoring are essential regardless of risk category
- • This tool is based on the EORTC risk tables but cannot replace clinical judgment